A detailed history of Pro Share Advisors LLC transactions in Akebia Therapeutics, Inc. stock. As of the latest transaction made, Pro Share Advisors LLC holds 39,308 shares of AKBA stock, worth $70,361. This represents 0.0% of its overall portfolio holdings.

Number of Shares
39,308
Holding current value
$70,361
% of portfolio
0.0%

Shares

23 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 13, 2024

BUY
$0.94 - $1.55 $36,949 - $60,927
39,308 New
39,308 $51,000
Q3 2022

Nov 04, 2022

BUY
$0.3 - $0.46 $351 - $539
1,172 Added 8.2%
15,465 $5,000
Q2 2022

Aug 01, 2022

SELL
$0.32 - $0.67 $11,684 - $24,464
-36,514 Reduced 71.87%
14,293 $5,000
Q1 2022

May 10, 2022

SELL
$0.72 - $2.93 $8,592 - $34,966
-11,934 Reduced 19.02%
50,807 $36,000
Q4 2021

Feb 08, 2022

BUY
$2.26 - $3.34 $7,021 - $10,377
3,107 Added 5.21%
62,741 $142,000
Q3 2021

Nov 12, 2021

SELL
$2.35 - $3.88 $24,881 - $41,081
-10,588 Reduced 15.08%
59,634 $172,000
Q2 2021

Aug 13, 2021

BUY
$2.83 - $4.2 $30,238 - $44,877
10,685 Added 17.95%
70,222 $266,000
Q1 2021

May 14, 2021

BUY
$2.92 - $5.06 $16,062 - $27,835
5,501 Added 10.18%
59,537 $202,000
Q4 2020

Feb 09, 2021

BUY
$2.22 - $3.78 $29,721 - $50,606
13,388 Added 32.94%
54,036 $151,000
Q3 2020

Nov 13, 2020

BUY
$2.39 - $13.08 $831 - $4,551
348 Added 0.86%
40,648 $102,000
Q2 2020

Aug 03, 2020

BUY
$6.67 - $13.58 $113,396 - $230,873
17,001 Added 72.97%
40,300 $547,000
Q1 2020

May 15, 2020

SELL
$4.1 - $10.24 $75,546 - $188,682
-18,426 Reduced 44.16%
23,299 $177,000
Q4 2019

Feb 12, 2020

SELL
$3.16 - $6.73 $12,327 - $26,253
-3,901 Reduced 8.55%
41,725 $264,000
Q3 2019

Nov 12, 2019

BUY
$3.55 - $5.4 $7,565 - $11,507
2,131 Added 4.9%
45,626 $179,000
Q2 2019

Aug 13, 2019

SELL
$4.1 - $8.05 $21,939 - $43,075
-5,351 Reduced 10.95%
43,495 $211,000
Q1 2019

May 15, 2019

BUY
$5.41 - $8.73 $110,888 - $178,938
20,497 Added 72.3%
48,846 $400,000
Q4 2018

Feb 14, 2019

SELL
$5.39 - $9.15 $5,815 - $9,872
-1,079 Reduced 3.67%
28,349 $157,000
Q3 2018

Nov 14, 2018

SELL
$7.44 - $10.65 $8,332 - $11,928
-1,120 Reduced 3.67%
29,428 $260,000
Q2 2018

Aug 13, 2018

BUY
$9.15 - $11.34 $27,193 - $33,702
2,972 Added 10.78%
30,548 $305,000
Q1 2018

May 14, 2018

SELL
$9.53 - $15.68 $43,209 - $71,093
-4,534 Reduced 14.12%
27,576 $263,000
Q4 2017

Feb 14, 2018

BUY
$14.24 - $19.59 $35,286 - $48,544
2,478 Added 8.36%
32,110 $477,000
Q3 2017

Nov 13, 2017

BUY
$13.06 - $19.67 $83,897 - $126,360
6,424 Added 27.68%
29,632 $583,000
Q2 2017

Aug 11, 2017

BUY
N/A
23,208
23,208 $333,000

Others Institutions Holding AKBA

About Akebia Therapeutics, Inc.


  • Ticker AKBA
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 183,848,992
  • Market Cap $329M
  • Description
  • Akebia Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics for patients with kidney diseases. The company's lead product investigational product candidate is vadadustat, an oral therapy, which is in Phase III development for the treatment of anemia due to chronic kidney disease (CKD) ...
More about AKBA
Track This Portfolio

Track Pro Share Advisors LLC Portfolio

Follow Pro Share Advisors LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Pro Share Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Pro Share Advisors LLC with notifications on news.